secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-05-23T23:59:59+00:00
Accession:  0001104659-25-052062
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin Pharma gets FDA clearance to start second pivotal Netherton Syndrome study for QRX003
--------------------------------------------------------------------------------

- FDA cleared Study CL-QRX003-002, testing whole-body QRX003 (~80% BSA) with off-label systemic therapy in ~12-15 subjects.
- Complements monotherapy pivotal study CL-QRX003-003 led by Dr. Amy Paller at Northwestern with up to 6 international sites.
- Five U.S. sites open; sixth expected in June; all sites have subject cohorts ready for rapid enrollment.
- Targets full recruitment into both pivotal studies by Q1 2026 and NDA filing later in 2026.
- Quoin claims only company running two late-stage whole-body pivotal NS studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925052062/0001104659-25-052062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925052062/tm2516001d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-052062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer